Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Sacharias Von Koch Added: 3 months ago
CRT 25 - Two-year outcomes of the Prevail paclitaxel-coated balloon show no difference in clinical outcomes compared to other drug-coated balloons (DCBs), suggesting the Prevail DCB is as effective and safe as other contemporary DCB's in a real-world setting. The Prevail DCB was also associated with lower rates of myocardial infarction in the sub-group analysis of patients who also underwent… View more
Author(s): Didier Tchétché Added: 1 year ago
Dr Didier Tchétché (Clinique Pasteur, Toulouse, FR) joins us to discuss findings from the SMART Trial.This prospective, multi-centre, randomised controlled study aims to investigate the valve safety and performance of self expanding as compared to balloon-expandable transcatheter aortic valve implantation (TAVI) in patients with small aortic annuli and severe symptomatic aortic stenosis. At… View more
Author(s): Marianne Brodmann Added: 4 months ago
ISET 2025 - How have drug delivery devices changed over the years, and what are the novel technologies and therapeutic agents?Dr Marianne Brodmann (Medical University of Graz, AT) joins us onsite at ISET 2025 to discuss the current landscape of drug delivery devices, from paclitaxel drug-coated balloons to drug-eluting stents. Dr Brodmann discusses evolving technologies, including bioresorbable… View more
Author(s): Ulf Teichgräber Added: 7 months ago
TCT Conference 2024 - Safety and efficacy outcomes of the trial shows that percutaneous transluminal angioplasty (PTA) with the sirolimus drug coated balloon (DCB) in patients with femoropopliteal artery disease was/was not noninferior to PTA with the paclitaxel DCB.Prof Ulf Teichgräber joins us onsite at TCT Conference to discuss the findings from the sirolimus- vs. paclitaxel-coated balloon… View more
Author(s): Ajay J Kirtane Added: 7 months ago
TCT Conference 2024 - Routine use of orbital atherectomy system (OAS) did not improve minimal stent area (MSA) or target vessel failure (TVF) at one year compaared to conventional balloon angioplasty.Dr Ajay J Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, New York, US) joins us onsite at TCT Conference to discuss the findings from ECLIPSE (NCT03108456; Abbott… View more
Author(s): Robert Yeh Added: 1 year ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more
Author(s): Howard C Herrmann Added: 1 year ago
ACC.24 — Investigator, Dr Howard C Hermann (Penn Medicine, Philadelphia, PA, US) joins us to discuss the findings from the SMART Trial (NCT04722250).This prospective, multi-center, randomized controlled study aims to investigate the valve safety and performance of self expanding as compared to balloon-expandable transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli… View more